User login
FDA approves new combination drug for heart failure
A combination of a new drug—sacubitril, a neprilysin inhibitor—and the angiotensin receptor blocker valsartan has been approved for the treatment of heart failure, providing what experts are describing as a major advance in the care of heart failure patients. The approval, announced by the Food and Drug Administration on July 7, 2015, was based on the PARADIGM-HF study of 8400 patients with heart failure, which found that the combination reduced the risk of cardiovascular death and hospitalization for heart failure by 20% and reduced the risk for all-cause mortality by 16%. To read the full article, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/fda-approval-of-sacubitril-valsartan-combo-opens-new-chapter-for-heart-failure/87f0d168e2c536251e452d008dc2671c.html.
A combination of a new drug—sacubitril, a neprilysin inhibitor—and the angiotensin receptor blocker valsartan has been approved for the treatment of heart failure, providing what experts are describing as a major advance in the care of heart failure patients. The approval, announced by the Food and Drug Administration on July 7, 2015, was based on the PARADIGM-HF study of 8400 patients with heart failure, which found that the combination reduced the risk of cardiovascular death and hospitalization for heart failure by 20% and reduced the risk for all-cause mortality by 16%. To read the full article, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/fda-approval-of-sacubitril-valsartan-combo-opens-new-chapter-for-heart-failure/87f0d168e2c536251e452d008dc2671c.html.
A combination of a new drug—sacubitril, a neprilysin inhibitor—and the angiotensin receptor blocker valsartan has been approved for the treatment of heart failure, providing what experts are describing as a major advance in the care of heart failure patients. The approval, announced by the Food and Drug Administration on July 7, 2015, was based on the PARADIGM-HF study of 8400 patients with heart failure, which found that the combination reduced the risk of cardiovascular death and hospitalization for heart failure by 20% and reduced the risk for all-cause mortality by 16%. To read the full article, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/fda-approval-of-sacubitril-valsartan-combo-opens-new-chapter-for-heart-failure/87f0d168e2c536251e452d008dc2671c.html.
Starting insulin in patients with type 2 diabetes: An individualized approach
Because type 2 diabetes mellitus is a progressive disease, most patients eventually need insulin. When and how to start insulin therapy are not one-size-fits-all decisions; rather, treatment must be individualized. This paper reviews the indications, goals, and options for insulin therapy in type 2 diabetes. To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/starting-insulin-in-patients-with-type-2-diabetes-an-individualized-approach/91326715dbccf29fbb7b1d9d93a420e5.html.
Because type 2 diabetes mellitus is a progressive disease, most patients eventually need insulin. When and how to start insulin therapy are not one-size-fits-all decisions; rather, treatment must be individualized. This paper reviews the indications, goals, and options for insulin therapy in type 2 diabetes. To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/starting-insulin-in-patients-with-type-2-diabetes-an-individualized-approach/91326715dbccf29fbb7b1d9d93a420e5.html.
Because type 2 diabetes mellitus is a progressive disease, most patients eventually need insulin. When and how to start insulin therapy are not one-size-fits-all decisions; rather, treatment must be individualized. This paper reviews the indications, goals, and options for insulin therapy in type 2 diabetes. To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/starting-insulin-in-patients-with-type-2-diabetes-an-individualized-approach/91326715dbccf29fbb7b1d9d93a420e5.html.
Understanding the overlap between COPD and asthma
To help physicians enhance their understanding of chronic obstructive pulmonary disease (COPD) and the asthma-COPD overlap syndrome (ACOS), the Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease have published Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS), which is available at http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf. This publication describes the features of ACOS, and includes a simple approach to its initial treatment.
To help physicians enhance their understanding of chronic obstructive pulmonary disease (COPD) and the asthma-COPD overlap syndrome (ACOS), the Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease have published Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS), which is available at http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf. This publication describes the features of ACOS, and includes a simple approach to its initial treatment.
To help physicians enhance their understanding of chronic obstructive pulmonary disease (COPD) and the asthma-COPD overlap syndrome (ACOS), the Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease have published Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS), which is available at http://www.goldcopd.org/uploads/users/files/AsthmaCOPDOverlap.pdf. This publication describes the features of ACOS, and includes a simple approach to its initial treatment.
A patient guide to anticoagulation
The American Heart Association offers a concise patient guide to anticoagulation. The guide, which is available at: http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/TheImpactofCongenitalHeartDefects/Anticoagulation_UCM_307110_Article.jsp, covers oral, intravenous, and subcutaneous anticoagulant medications, the need for medication monitoring, and precautions to take for women who need anticoagulation during pregnancy.
The American Heart Association offers a concise patient guide to anticoagulation. The guide, which is available at: http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/TheImpactofCongenitalHeartDefects/Anticoagulation_UCM_307110_Article.jsp, covers oral, intravenous, and subcutaneous anticoagulant medications, the need for medication monitoring, and precautions to take for women who need anticoagulation during pregnancy.
The American Heart Association offers a concise patient guide to anticoagulation. The guide, which is available at: http://www.heart.org/HEARTORG/Conditions/CongenitalHeartDefects/TheImpactofCongenitalHeartDefects/Anticoagulation_UCM_307110_Article.jsp, covers oral, intravenous, and subcutaneous anticoagulant medications, the need for medication monitoring, and precautions to take for women who need anticoagulation during pregnancy.
Tips for Coping With Migraine
Tips for Coping With Traumatic Brain Injury
How do stroke and sleep apnea affect cognition?
Patients with stroke and sleep apnea may have worse memory and executive function than individuals with sleep apnea alone, stroke alone, or neither diagnosis, according to research presented at the 67th Annual Meeting of the American Academy of Neurology. To read the full article, go to Neurology Reviews.
Patients with stroke and sleep apnea may have worse memory and executive function than individuals with sleep apnea alone, stroke alone, or neither diagnosis, according to research presented at the 67th Annual Meeting of the American Academy of Neurology. To read the full article, go to Neurology Reviews.
Patients with stroke and sleep apnea may have worse memory and executive function than individuals with sleep apnea alone, stroke alone, or neither diagnosis, according to research presented at the 67th Annual Meeting of the American Academy of Neurology. To read the full article, go to Neurology Reviews.
Weighing the options for obesity meds
When lifestyle interventions alone are insufficient to help patients lose weight, pharmacotherapy may be indicated. This review covers what to assess before prescribing one of the 5 US Food and Drug Administration-approved medications for chronic weight loss: orlistat, lorcaserin, phentermine/topiramate, bupropion/naltrexone, and liraglutide. To read the full article, go to Clinician Reviews: http://www.clinicianreviews.com/specialty-focus/endocrinology-metabolism/article/weighing-the-options-for-obesity-meds/ed4de5e0a96247503e79f467f2598ab3.html.
When lifestyle interventions alone are insufficient to help patients lose weight, pharmacotherapy may be indicated. This review covers what to assess before prescribing one of the 5 US Food and Drug Administration-approved medications for chronic weight loss: orlistat, lorcaserin, phentermine/topiramate, bupropion/naltrexone, and liraglutide. To read the full article, go to Clinician Reviews: http://www.clinicianreviews.com/specialty-focus/endocrinology-metabolism/article/weighing-the-options-for-obesity-meds/ed4de5e0a96247503e79f467f2598ab3.html.
When lifestyle interventions alone are insufficient to help patients lose weight, pharmacotherapy may be indicated. This review covers what to assess before prescribing one of the 5 US Food and Drug Administration-approved medications for chronic weight loss: orlistat, lorcaserin, phentermine/topiramate, bupropion/naltrexone, and liraglutide. To read the full article, go to Clinician Reviews: http://www.clinicianreviews.com/specialty-focus/endocrinology-metabolism/article/weighing-the-options-for-obesity-meds/ed4de5e0a96247503e79f467f2598ab3.html.
CDC guidance on hepatitis C counseling and testing
The Centers for Disease Control and Prevention’s A Guide to Comprehensive Hepatitis C Testing and Counseling focuses on identifying hepatitis C infection in adults born between 1945 and 1965. The guide, which is available at http://www.cdc.gov/hepatitis/resources/professionals/pdfs/counselingandtestingpc.pdf, explains why these patients need to be tested, covers testing recommendations, and describes how to counsel patients about the results. (Sample scripts are included.)
The Centers for Disease Control and Prevention’s A Guide to Comprehensive Hepatitis C Testing and Counseling focuses on identifying hepatitis C infection in adults born between 1945 and 1965. The guide, which is available at http://www.cdc.gov/hepatitis/resources/professionals/pdfs/counselingandtestingpc.pdf, explains why these patients need to be tested, covers testing recommendations, and describes how to counsel patients about the results. (Sample scripts are included.)
The Centers for Disease Control and Prevention’s A Guide to Comprehensive Hepatitis C Testing and Counseling focuses on identifying hepatitis C infection in adults born between 1945 and 1965. The guide, which is available at http://www.cdc.gov/hepatitis/resources/professionals/pdfs/counselingandtestingpc.pdf, explains why these patients need to be tested, covers testing recommendations, and describes how to counsel patients about the results. (Sample scripts are included.)
Heart failure readmissions? Suspect senile amyloidosis
Even when a patient is repeatedly admitted to the hospital for heart failure exacerbations, the underlying cause may be missed. One possible cause is senile amyloidosis, as this case from the Albert Einstein Medical Center in Philadelphia makes clear. To read the full article, go to Federal Practitioner: http://www.fedprac.com/specialty-focus/cardiovascular-disease/article/heart-failure-readmissions-suspect-senile-amyloidosis/e838106919f474ff322f82ba1440bb77/ocregister.html
Even when a patient is repeatedly admitted to the hospital for heart failure exacerbations, the underlying cause may be missed. One possible cause is senile amyloidosis, as this case from the Albert Einstein Medical Center in Philadelphia makes clear. To read the full article, go to Federal Practitioner: http://www.fedprac.com/specialty-focus/cardiovascular-disease/article/heart-failure-readmissions-suspect-senile-amyloidosis/e838106919f474ff322f82ba1440bb77/ocregister.html
Even when a patient is repeatedly admitted to the hospital for heart failure exacerbations, the underlying cause may be missed. One possible cause is senile amyloidosis, as this case from the Albert Einstein Medical Center in Philadelphia makes clear. To read the full article, go to Federal Practitioner: http://www.fedprac.com/specialty-focus/cardiovascular-disease/article/heart-failure-readmissions-suspect-senile-amyloidosis/e838106919f474ff322f82ba1440bb77/ocregister.html